Related references
Note: Only part of the references are listed.The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
Gerlincle Wernig et al.
BLOOD (2008)
The JAK2V617F mutation can occur in a hematopoietic stem cell that exhibits no proliferative advantage:: a case of human allogeneic transplantation
Kristien Van Pelt et al.
BLOOD (2008)
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
Ralph Tiedt et al.
BLOOD (2008)
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases
Jean-Jacques Kiladjian et al.
BLOOD (2008)
Selective inhibition of JAK2-Driven erythroid differentiation of polycythemia vera progenitors
Ifat Geron et al.
CANCER CELL (2008)
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera
Gerlinde Werning et al.
CANCER CELL (2008)
Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers
Eun Goo Jeong et al.
CLINICAL CANCER RESEARCH (2008)
20+yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis
Ayalew Tefferi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1low mouse model of the disease
Anna Rita Migliaccio et al.
EXPERIMENTAL HEMATOLOGY (2008)
Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2
Alexandra Dusa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia
Elisabetta Flex et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Downregulation of signal transducer and activator of transcription 5 (STAT5) in CD34(+) cells promotes megakaryocytic development, whereas activation of STAT5 drives erythropoiesis
Sandra G. Olthof et al.
STEM CELLS (2008)
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F
V. Guerini et al.
LEUKEMIA (2008)
JAK kinases overexpression promotes in vitro cell transformation
L. Knoops et al.
ONCOGENE (2008)
Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders
Animesh Pardanani et al.
BLOOD (2008)
Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity
Megumi Funakoshi-Tago et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F
Xiaohui Lu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients
C. M. Butcher et al.
LEUKEMIA (2008)
Epigenetic control of PRV-1 expression on neutrophils
Jaroslav Jelinek et al.
EXPERIMENTAL HEMATOLOGY (2007)
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer
Kornel E. Schuebel et al.
PLOS GENETICS (2007)
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations
A. Pardanani et al.
LEUKEMIA (2007)
JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder
A. Pardanani et al.
LEUKEMIA (2007)
Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation
Naseema Gangat et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera
Sabrina Dupont et al.
BLOOD (2007)
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis
Stefan O. Ciurea et al.
BLOOD (2007)
Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation
Luciana Teofili et al.
BLOOD (2007)
Leukemic blasts in transfon-ned JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation
Alexandre Theocharides et al.
BLOOD (2007)
Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis
Jun Shi et al.
CANCER RESEARCH (2007)
The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3
Michelle B. Hookham et al.
BLOOD (2007)
Imatinib effect on growth and signal transduction in polycythemia vera
Amos Gaikwad et al.
EXPERIMENTAL HEMATOLOGY (2007)
The expression of CXCR4 is down-regulated on the CD34+cells of patients with myelofibrosis with myeloid metaplasia
Vittorio Rosti et al.
BLOOD CELLS MOLECULES AND DISEASES (2007)
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth
Zhe Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Jak2: normal function and role in hematopoietic disorders
James N. Ihle et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2007)
Granulocyte colony-stimulating factor and its receptor in normal myeloid cell development, leukemia and related blood cell disorders
Ivo P. Touw et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2007)
Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders
E. Jost et al.
LEUKEMIA (2007)
Polycythemia vera is not initiated by JAK2(V17F) mutation
Roberto H. Nussenzveig et al.
EXPERIMENTAL HEMATOLOGY (2007)
Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis
Francois Delhommeau et al.
BLOOD (2007)
SOCS proteins, cytokine signalling and immune regulation
Akihiko Yoshimura et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F
Virginia M. Zaleskas et al.
PLOS ONE (2006)
Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression
Alison R. Moliterno et al.
BLOOD (2006)
Characterization of murine JAK2V617F-positive myeloproliferative disease
Thomas G. P. Bumm et al.
CANCER RESEARCH (2006)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2
Megumi Funakoshi-Tago et al.
EMBO JOURNAL (2006)
Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia
Linda M. Scott et al.
BLOOD (2006)
Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia
R. A. Mesa et al.
LEUKEMIA (2006)
JAK signaling globally counteracts heterochromatic gene silencing
Song Shi et al.
NATURE GENETICS (2006)
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders
Robert Kralovics et al.
BLOOD (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome
Raj K. Patel et al.
GASTROENTEROLOGY (2006)
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model
Gerlinde Wernig et al.
BLOOD (2006)
Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells
A Zeuner et al.
BLOOD (2006)
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders
F Passamonti et al.
BLOOD (2006)
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation
CHM Jamieson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha
AV Jones et al.
BLOOD (2006)
The hematopoietic stem compartment consists of a limited number of discrete stem cell subsets
HB Sieburg et al.
BLOOD (2006)
An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor
J Staerk et al.
BLOOD (2006)
Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway
W Zhao et al.
BLOOD (2006)
JAK2(V617F) expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis
Catherine Lacout et al.
BLOOD (2006)
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation
XH Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation - Cross-talk with IGF1 receptor
J Staerk et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study
PJ Campbell et al.
LANCET (2005)
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
R Kralovics et al.
BLOOD (2005)
Identification of JAK/STAT signalling components by genome-wide RNA interference
P Müller et al.
NATURE (2005)
Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-β signaling
BJ Jenkins et al.
NATURE MEDICINE (2005)
Janus kinases affect thrombopoietin receptor cell surface localization and stability
Y Royer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Identification of an acquired JAK2 mutation in Polycythemia vera
RX Zhao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways
W Tong et al.
BLOOD (2005)
Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases
MJ Xu et al.
BLOOD (2005)
A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-β1 in the development of myelofibrosis
AM Vannucchi et al.
BLOOD (2005)
The threshold of gp130-dependent STAT3 signaling is critical for normal regulation of hematopoiesis
BJ Jenkins et al.
BLOOD (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist
HE Broxmeyer et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Kinase activation through dimerization by human SH2-B
M Nishi et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB
CH Dai et al.
EXPERIMENTAL HEMATOLOGY (2005)
Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-Bβ
JH Kurzer et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera
V Ugo et al.
EXPERIMENTAL HEMATOLOGY (2004)
Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis
W Tong et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Janus kinase (Jak) subcellular localization revisited -: The exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak•receptor complex to be equivalent to a receptor tyrosine kinase
I Behrmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Determination of the transphosphorylation sites of Jak2 kinase
T Matsuda et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity
LS Argetsinger et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling
EP Feener et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin
F Ding et al.
BLOOD (2004)
Internalization of the thrombopoietin receptor is regulated by 2 cytoplasmic motifs
DD Dahlen et al.
BLOOD (2003)
The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression
J Ragimbeau et al.
EMBO JOURNAL (2003)
Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer
N Seubert et al.
MOLECULAR CELL (2003)
The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction
P Saharinen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Prominent role of TGF-β1 in thrombopoietin-induced myelofibrosis in mice
H Chagraoui et al.
BLOOD (2002)
Transcriptional regulation of erythropoiesis: an affair involving multiple partners
AB Cantor et al.
ONCOGENE (2002)
A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor
M Hörtner et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2002)
Requirement for mitogen-activated protein kinase activation in the response of embryonic stem cell-derived hematopoietic cells to thrombopoietin in vitro
MD Filippi et al.
BLOOD (2002)
Identification of the human erythropoietin receptor region required for Stat1 and Stat3 activation
K Kirito et al.
BLOOD (2002)
The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor
LJS Huang et al.
MOLECULAR CELL (2001)
STAT3 is constitutively active in some patients with Polycythemia rubra vera
S Röder et al.
EXPERIMENTAL HEMATOLOGY (2001)
Inn-eased expression of the INK4a/ARF locus in polycythemia vera
CH Dai et al.
BLOOD (2001)
Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras
NA Cacalano et al.
NATURE CELL BIOLOGY (2001)
Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain
SN Constantinescu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Involvement of the fibrogenic cytokines, TGF-β and bFGF, in the pathogenesis of idiopathic myelofibrosis
MC Le Bousse-Kerdilès et al.
PATHOLOGIE BIOLOGIE (2001)
The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif
SN Constantinescu et al.
MOLECULAR CELL (2001)
Thrombopoietin induces phosphoinositol 3-kinase activation through SHP2, Gab, and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytes
Y Miyakawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation
K Lindauer et al.
PROTEIN ENGINEERING (2001)
A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-α signaling
TC Yeh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130
SE Nicholson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Regulation of the Jak2 tyrosine kinase by its pseudokinase domain
P Saharinen et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130
J Schmitz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
